RA
PRCT icon

RiverPark Advisors’s Procept Biorobotics PRCT Stock Holding History

RiverPark Advisors’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,761
Closed -$101K – 151
2025
Q2 		$101K Buy
1,761
+324
+23% +$18.3K 0.06% 104
2025
Q1 		$83.7K Sell
1,437
-1,278
-47% -$87.3K 0.07% 100
2024
Q4 		$253K Sell
2,715
-477
-15% -$40.8K 0.2% 74
2024
Q3 		$256K Buy
3,192
+981
+44% +$69.7K 0.21% 75
2024
Q2 		$135K Buy
+2,211
New +$131K 0.11% 91

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

RiverPark Advisors's PRCT Position: Q3 2025 in Review

RiverPark Advisors sold out of Procept Biorobotics (PRCT) in Q3 2025, closing a stake of 1,761 shares — an estimated $101K sold.

RiverPark Advisors first reported a position in PRCT in Q2 2024 and held it in 5 quarters. The position peaked at $256K in Q3 2024. 242 funds tracked by Wall St. Rank hold PRCT as of Q3 2025.

  • RiverPark Advisors reported no remaining Procept Biorobotics position as of Q3 2025 after selling out during the quarter.
  • RiverPark Advisors sold 1,761 Procept Biorobotics shares in Q3 2025, an estimated $101K.
  • RiverPark Advisors first reported a position in Procept Biorobotics in Q2 2024 and held it in 5 quarters.
  • RiverPark Advisors's Procept Biorobotics position peaked at $256K in Q3 2024.
  • 242 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2025.

Based on RiverPark Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.